Loading…
Concord Biotech (CONCORDBIO)₹596.80−2.52%Pharmaceuticals
In the Sep 2026 quarter (consolidated), Concord Biotech reported sales of ₹308 Cr, up 25.2% from Sep 2025, and net profit of ₹69.71 Cr, up 11.0% year on year. For the year to Mar 2026, sales were ₹1,052 Cr and net profit ₹258 Cr.
Company filings, consolidated accounts; latest reported quarter Sep 2026
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 240 | 318 | 215 | 309 | 243 | 429 | 203 | 246 | 277 | 325 | 256 | 308 |
| Expenses | 135 | 187 | 135 | 176 | 146 | 241 | 143 | 159 | 179 | 208 | 175 | 205 |
| Operating Profit | 106 | 132 | 81.04 | 134 | 97.95 | 189 | 60.99 | 88.05 | 97.97 | 118 | 82.02 | 104 |
| OPM % | 44.0% | 41.0% | 38.0% | 43.0% | 40.0% | 44.0% | 30.0% | 36.0% | 34.9% | 35.9% | 32.0% | 33.9% |
| Other Income | 10.96 | 10.97 | 11.97 | 9.97 | 16.97 | 8.98 | 14.96 | 15.96 | 6.98 | 14.95 | 13.97 | 9.98 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 14.02 | 14.02 | 13.02 | 13.01 | 13.01 | 15.02 | 18.01 | 18.01 | 19.01 | 20.02 | 18.01 | 18.01 |
| Profit before tax | 103 | 129 | 80.06 | 130 | 101 | 184 | 58.96 | 86.06 | 85.98 | 114 | 78.06 | 94.93 |
| Tax % | 25.0% | 26.0% | 25.0% | 27.0% | 25.0% | 24.0% | 25.0% | 26.0% | 26.1% | 22.0% | 26.0% | 27.0% |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | −2.01 | 0.00 | 0.00 | 0.00 |
| Net Profit | 77.76 | 94.62 | 59.81 | 95.64 | 75.70 | 140 | 43.88 | 62.80 | 63.80 | 87.65 | 57.77 | 69.71 |
| EPS (Rs) | 7.40 | 9.07 | 5.71 | 9.14 | 7.25 | 13.41 | 4.20 | 6.09 | 6.15 | 8.48 | 5.60 | 6.74 |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|
| Sales | 510 | 614 | 711 | 850 | 1,014 | 1,197 | 1,052 | 1,166 |
| Expenses | 309 | 290 | 444 | 509 | 586 | 695 | 688 | 768 |
| Operating Profit | 205 | 327 | 270 | 344 | 432 | 506 | 368 | 402 |
| OPM % | 39.9% | 53.0% | 38.0% | 40.0% | 42.0% | 42.0% | 34.9% | 34.5% |
| Other Income | 31.90 | 13.97 | 22.95 | 36.89 | 36.89 | 43.91 | 51.83 | 45.88 |
| Interest | 0.99 | 0.99 | 5.99 | 4.99 | 2.99 | 1.01 | 1.01 | 0.00 |
| Depreciation | 21.03 | 28.01 | 50.02 | 54.07 | 54.07 | 54.06 | 74.06 | 75.05 |
| Profit before tax | 214 | 313 | 238 | 322 | 413 | 495 | 345 | 373 |
| Tax % | 21.0% | 25.0% | 26.0% | 25.0% | 25.0% | 25.0% | 25.0% | — |
| Exceptional items | 17.05 | 5.01 | 4.01 | 3.01 | 11.04 | 28.08 | 22.08 | −2.01 |
| Net Profit | 168 | 234 | 174 | 239 | 307 | 371 | 258 | 279 |
| EPS (Rs) | 16.16 | 22.51 | 16.71 | 22.94 | 29.43 | 35.51 | 24.92 | 26.97 |
| Dividend payout % | 22.0% | 0.0% | 3.0% | 29.9% | 29.9% | 25.0% | 29.9% | — |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 9.97 | 9.97 | 9.97 | 9.96 | 9.97 | 9.97 | 9.97 |
| Reserves | 760 | 988 | 1,091 | 1,278 | 1,514 | 1,799 | 2,005 |
| Borrowings | 52.00 | 85.87 | 61.83 | 31.95 | 9.98 | 2.99 | 1.99 |
| Other Liabilities | 117 | 96.53 | 146 | 191 | 163 | 218 | 211 |
| Total Liabilities | 940 | 1,181 | 1,310 | 1,511 | 1,698 | 2,030 | 2,229 |
| Fixed Assets | 240 | 545 | 572 | 592 | 574 | 794 | 787 |
| CWIP | 141 | 17.97 | 73.92 | 173 | 211 | 50.95 | 78.88 |
| Investments | 200 | 141 | 74.19 | 138 | 247 | 336 | 493 |
| Other Assets | 360 | 475 | 589 | 609 | 665 | 850 | 870 |
| Inventories | 111 | 154 | 195 | 212 | 208 | 240 | 326 |
| Trade receivables | 185 | 178 | 233 | 275 | 351 | 524 | 461 |
| Cash & equivalents | 3.01 | 61.18 | 89.28 | 43.12 | 47.11 | 1.01 | 14.03 |
| Total Assets | 940 | 1,181 | 1,310 | 1,511 | 1,698 | 2,030 | 2,229 |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Cash from operating activity | 154 | 166 | 207 | 245 | 264 | 244 | 266 |
| Cash from investing activity | −114 | −195 | −112 | −158 | −155 | −160 | −143 |
| Cash from financing activity | −42.88 | 30.87 | −99.64 | −84.69 | −98.66 | −98.65 | −113 |
| Net cash flow | −0.99 | 2.99 | −3.99 | 2.99 | 11.98 | −13.98 | 10.99 |
| Capex | 156 | 203 | 155 | 145 | 85.75 | 111 | 94.70 |
| Free cash flow | −0.99 | −37.87 | 51.86 | 101 | 179 | 134 | 171 |
| CFO / OP % | 100.0% | 74.0% | 99.1% | 92.0% | 85.0% | 70.0% | 100.0% |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Debtor days | 131 | 105 | 119 | 117 | 125 | 159 | 159 |
| Inventory days | 312 | 503 | 434 | 430 | 331 | 286 | 485 |
| Days payable | 201 | 152 | 185 | 190 | 150 | 135 | 151 |
| Cash conversion cycle | 243 | 457 | 369 | 358 | 307 | 311 | 494 |
| Working capital days | 158 | 176 | 160 | 151 | 165 | 192 | 229 |
| ROCE % | — | 32.0% | 21.0% | 26.0% | 28.0% | 28.0% | 17.0% |
For the Sep 2026 quarter, Concord Biotech reported sales of ₹308 Cr, up 25.2% year on year and net profit of ₹69.71 Cr, up 11.0% year on year. The operating margin was 33.9%.
Concord Biotech's sales for the year to Mar 2026 were ₹1,052 Cr; over the last twelve months they were ₹1,166 Cr.
Net profit for the year to Mar 2026 was ₹258 Cr, and ₹279 Cr over the last twelve months. Earnings per share over the same trailing period were ₹26.97.
Concord Biotech reported borrowings of ₹1.99 Cr at Mar 2026, against cash and equivalents of ₹14.03 Cr.
Cash from operations was ₹266 Cr in the year to Mar 2026; after capital spending, free cash flow was ₹171 Cr.